Plain-English translation of NCT06856850 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are looking for biological markers — measurable signs in the body — that can help diagnose and better understand ALS and frontotemporal dementia. These two conditions often overlap and share similar causes, but doctors don't yet have reliable ways to tell them apart or predict how they'll progress. This study will collect samples from skin, tears, mucus membranes, blood, and spinal fluid to uncover new clues about how these diseases develop.
Right now, diagnosing ALS and frontotemporal dementia can be slow and uncertain because there aren't reliable biological markers to identify them. This research aims to fill that gap by examining easily accessible tissues that haven't been thoroughly studied before, which could lead to faster, more accurate diagnoses and better ways to track treatment progress.
You likely qualify if…
You likely don't qualify if…
You would be asked to provide samples from different parts of your body — including blood, tears, skin, and possibly fluid from your nose or spinal cord — which researchers will analyze to find disease markers. The study will also look at existing samples already collected from similar patients. Visits and timeline details aren't fully specified yet, but the researchers expect to enroll about 230 people total.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Italy